39 results about "Subjective tinnitus" patented technology

The invention comprises a totally implantable hearing prosthesis for hearing impaired persons. An inertial vibrational element is hermetically sealed and implanted in bone between the lateral and superior semicircular canals without breaching the integrity of the canals. The vibrational element is adapted to vibrate the walls of the canals and the fluids contained therein, thereby vibrating contiguous fluids within the cochlea thus stimulating hair cells and creating a hearing percept. The invention can also be adapted to be a tinnitus masking system, and/or used in combination with a coehlear implant hearing system.

A system according to the present invention provides a portable, non-invasive device adapted to deliver electrical stimulation to a brain, such as to treat tinnitus. Such system is preferably a head-worn system configured to provide transcranial direct current electrical stimulation (tDCS) to a patient, where a therapy based at least partially thereon may be self-administered by the patient. tDCS is a non-invasive method of brain stimulation to treat tinnitus, or other neurological indications, that may provide significant relief. Methods according to the present invention include preferably brief sessions of anodal tDCS to assist in determining adequate electrode location and stimulus intensity by producing transient decreases in tinnitus intensity. Methods may also or alternatively include a number of sessions of cathodal tDCS at a confirmed electrode location and stimulus intensity to provide sustained tinnitus relief. Methods may also or alternatively include a number of maintenance sessions to prolong the sustained relief.

The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, sudden deafness, or other cochlear excitotoxic-inducing occurrence.

This invention relates to compounds, compositions, and methods useful for modulating retinoblastoma (RB1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of retinoblastoma gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of retinoblastoma genes. Such small nucleic acid molecules are useful, for example, for treating, preventing, inhibiting, or reducing hearing loss, deafness, tinnitus, motion and balance disorders, cancer and proliferative diseases and any other disease, condition, trait or indication that can respond to the level of retinoblastoma in a cell or tissue, alone or in combination with other treatments or therapies.

The present invention relates to implantable medical devices for improving sound perception by individuals with severe to profound hearing loss or tinnitus. In particular, the present invention provides methods and devices for stimulating structures of the ear via multiple signal transducers.

A tinnitus treatment device includes a sound generation device and a receiver unit connected to the sound generation device. The receiver unit is positioned in an open-ear configuration within the ear canal of a user and is dimensioned so as to reduce insertion loss and/or occlusion effects. The sound generation device is located in a housing positioned behind the user's ear.

Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein, , R¹, R², R^3a, R^3b, R^4a, and R^4b are as defined herein, and A is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

Method for accurately measuring hearing loss includes the steps of selecting a series of audio tones within the normal range of hearing (502) and then measuring a relative sensitivity of a test subject with respect to the ability to hear each of the audio tones, exclusive of the effects of tinnitus. (504, 506, 508, 510, 512) The relative sensitivity of the test subject to hear the tones can be measured by determining (510) for each tone an intensity necessary for the test subject to hear the tones at a subjectively equal loudness level which is selected to exceed a perceived level of noise attributable to tinnitus for the test subject.

A soft, ball-shaped middle-ear electrode is inserted and wedged into the natural cavity that exists in front of the round window. An electrical pulse generator connected to the soft, ball-shaped electrode provides electrical stimulation to the region surrounding the round window for the purpose of suppressing tinnitus or to improve hearing.

A method of treating an otological disorder in a patient in need thereof, the method comprising administering to the patient ambroxol or a pharmacologically acceptable salt thereof.

The invention relates to a traditional Chinese medicine decoction piece preparation, and concretely relates to a traditional Chinese medicine decoction piece combination preparation enhancing body immunity, a preparation method therefor and combination package. The raw materials of the traditional Chinese medicine decoction piece combination preparation are composed of radix ophiopogonis, Chinese magnoliavine, prepared rehmannia root, cornus officinalis, tree peony bark, Chinese yam, poria cocos and oriental waterplantain rhizome. The traditional Chinese medicine decoction piece combination preparation has effects of nourishing kidney and lung, is used for treating lung and kidney yin deficiency, tidal fever, night sweating, pharynx dryness, dizziness, tinnitus and soreness of loins and knees, can enhance body immunity and has functions of anti-fatigue and conditioning of the sub-health state.

The invention discloses a health-care red wine and a preparation method thereof. The red wine base of the health-care red wine also comprises the following raw materials: 0.5-1.5 g/L raspberry, 0.01-1.5 g/L Rhodiola rosea, 0.01-1.5 g/L dodder, 0.01-1.5 g/L radix rehmanniae, 0.1-1 g/L Chinese wolfberry, 0.1-1 g/L mulberry, 0.05-0.8 g/L radix astragali, 0.05-0.8 g/L tuckahoe and 0.01-0.8 g/L licorice. The health-care red wine is prepared from multiple medicinal materials, has the functions of consolidating the constitution, benefiting the intestine, tonifying the kidney, strengthening the spleen, regulating sleep, warming the stomach, resisting aging and softening the blood vessels, has obvious effects on regulating frequent urination, precipitant urination, insomnia and discomfort caused by heart and cerebral vessels, and can relieve dizziness, tinnitus, nausea and other symptoms caused by cervical spondylosis.

The present invention relates to preventive and/or therapeutic agents for Meniere's disease, which comprise a leukotriene antagonist (such as pranlukast hydrate) as an active ingredient. Leukotriene antagonists (such as pranlukast hydrate) are effective in ameliorating various symptoms, such as hearing impairment, tinnitus, a feeling of fullness in the ear and vertigo, thus being useful as a preventive and/or therapeutic agent for Meniere's disease.

Substituted 5-aminomethyl-1H-pyrrole-2-carboxylic acid amides, a process for the production thereof, pharmaceutical preparations containing these compounds and the use of these compounds in pharmaceutical preparations for treatment or inhibition of withdrawal symptoms, memory disorders, neurodegenerative diseases, epilepsy, cardiovascular disorders, water retention, intestinal motility disorders, urinary incontinence, anorexia, tinnitus, pruritus, depression, sexual dysfunction, airways diseases, food intake disorders, or type II (non-insulin-dependent) diabetes, or for anxiolysis, diuresis, suppression of the urinary reflex, reducing the addictive potential of opioids, modulating locomotor activity, influencing the cardiovascular system, or regulating electrolyte balance.

Novel methods and compositions for the local treatment of Meniere's disease, tinnitus and hearing loss employ a therapeutically effective amount of a prostaglandin of the F-type to the inner ear. The treatment can be either continuous or intermittent and may involve the use of pumps, gels, or slow release drug inserts.